Endocrinology · Male Hypogonadism
The facts most likely to be tested
The initial diagnostic step for suspected hypogonadism is a morning serum total testosterone level measured between 8:00 AM and 10:00 AM.
Primary hypogonadism (hypergonadotropic) is characterized by low testosterone and elevated FSH and LH levels due to testicular failure.
Secondary hypogonadism (hypogonadotropic) is characterized by low testosterone and low or inappropriately normal FSH and LH levels due to hypothalamic or pituitary dysfunction.
Klinefelter syndrome (47,XXY) is the most common cause of primary hypogonadism, presenting with small, firm testes, gynecomastia, and tall stature.
Kallmann syndrome is a form of secondary hypogonadism caused by a failure of GnRH-secreting neurons to migrate, classically presenting with hypogonadism and anosmia.
Prolactinoma is a high-yield cause of secondary hypogonadism that suppresses GnRH pulsatility, often presenting with galactorrhea and bitemporal hemianopsia.
Testosterone replacement therapy is contraindicated in patients with prostate cancer or breast cancer due to the risk of tumor stimulation.
Vignette unlocked
A 24-year-old male presents to the clinic complaining of a lack of sexual development and an inability to smell his surroundings. Physical examination reveals sparse axillary and pubic hair, small testes, and a eunuchoid habitus. Laboratory studies demonstrate a low serum total testosterone, low LH, and low FSH. The patient has no history of head trauma or pituitary surgery.
What is the most likely diagnosis?
Kallmann syndrome
The combination of hypogonadotropic hypogonadism (low T, low LH/FSH) and anosmia is pathognomonic for Kallmann syndrome, which is tested as a failure of GnRH neuron migration.
Full handout
High yield triage
Etiology / Epidemiology
Primary (testicular) vs. Secondary (hypothalamic/pituitary) failure. Obesity, aging, and opioid use are major risk factors.
Clinical Manifestations
Loss of libido, erectile dysfunction, and gynecomastia. Decreased morning erections is a highly sensitive clinical marker.
Diagnosis
Morning serum total testosterone < 300 ng/dL on two separate occasions is the gold standard diagnostic threshold.
Treatment
Testosterone replacement therapy (TRT) is first-line. Contraindicated in prostate or breast cancer.
Prognosis
Long-term therapy requires monitoring hematocrit and PSA levels to prevent polycythemia and prostate progression.
Full handout
Epidemiology & Etiology
Primary hypogonadism results from testicular failure (e.g., Klinefelter syndrome, mumps orchitis). Secondary hypogonadism stems from hypothalamic-pituitary axis disruption, often due to hyperprolactinemia, pituitary adenomas, or chronic opioid use. Prevalence increases significantly with age and metabolic syndrome.
Pertinent Anatomy
The hypothalamic-pituitary-gonadal axis regulates androgen production. The hypothalamus releases GnRH, stimulating the anterior pituitary to secrete LH and FSH, which act on Leydig and Sertoli cells in the testes.
Pathophysiology
In primary hypogonadism, low testosterone leads to elevated LH/FSH due to loss of negative feedback. In secondary hypogonadism, both testosterone and LH/FSH are low or inappropriately normal. Chronic deficiency leads to loss of muscle mass, bone density, and metabolic shifts.
Clinical Manifestations
Patients present with fatigue, depression, and sexual dysfunction. Physical exam may reveal small, firm testes in Klinefelter syndrome or gynecomastia. Red flags include sudden vision changes suggesting a pituitary mass or severe headaches.
Diagnosis
Order morning serum total testosterone (8-10 AM) as the gold standard initial screen. If low, repeat with LH/FSH to differentiate primary (high LH/FSH) from secondary (low/normal LH/FSH). A threshold of < 300 ng/dL confirms the diagnosis.
Treatment
Testosterone replacement therapy (TRT) via transdermal gels or intramuscular injections is the standard. Contraindications include active prostate/breast cancer, untreated sleep apnea, and severe heart failure. Monitor for erythrocytosis and worsening of lower urinary tract symptoms.
Prognosis
Treatment improves libido, mood, and bone mineral density. Patients require periodic monitoring of hematocrit (target < 54%) and PSA levels to ensure safety and efficacy.
Differential Diagnosis
Hyperprolactinemia: elevated prolactin suppresses GnRH
Kallmann syndrome: anosmia with hypogonadotropic hypogonadism
Klinefelter syndrome: 47,XXY karyotype with small testes
Hemochromatosis: iron deposition in the pituitary gland
Aging: age-related decline in testosterone production